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lower uptake estimation in PET/MRI, partially justified by bio-redistribution. The clinical evaluation
showed that PET/MRI offers higher image quality and sharpness with lower levels of noise and artifacts
compared to PET/CT with reduced acquisition times for whole-body scans while for brain scans there is
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Abstract
Purpose: The purpose of this study was to compare only the performance of the PET component
between a TOF-PET/CT (henceforth noted as PET/CT) scanner and an integrated TOF-PET/
MRI (henceforth noted as PET/MRI) scanner concerning image quality parameters and
quantification in terms of standardized uptake value (SUV) as a function of acquisition time (a
surrogate of dose). The CT and MR image quality were not assessed, and that is beyond the
scope of this study.
Procedures: Five brain and five whole-body patients were included in the study. The PET/CT
scan was used as a reference and the PET/MRI acquisition time was consecutively adjusted,
taking into account the decay between the scans in order to expose both systems to the same
amount of the emitted signal. The acquisition times were then retrospectively reduced to assess
the performance of the PET/MRI for lower count rates. Image quality, image sharpness, artifacts,
and noise were evaluated. SUV measurements were taken in the liver and in the white matter to
compare quantification.
Results: Quantitative evaluation showed strong correlation between PET/CT and PET/MRI brain
SUVs. Liver correlation was good, however, with lower uptake estimation in PET/MRI, partially
justified by bio-redistribution. The clinical evaluation showed that PET/MRI offers higher image
quality and sharpness with lower levels of noise and artifacts compared to PET/CT with reduced
acquisition times for whole-body scans while for brain scans there is no significant difference.
Conclusion: The TOF-PET/MRI showed higher image quality compared to TOF-PET/CT as
tested with reduced imaging times. However, this result accounts mainly for body imaging, while
no significant differences were found in brain imaging.
Key words: Image quality, PET/MRI, PET/CT, Solid-state PET detectors, Time-of-flight, Dose
reduction
Introduction
In a clinical world where PET/CT has proven its diagnosticexcellence after its introduction roughly a decade ago [1],
the recently available integrated PET/MRI imaging can offer
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significant additional advances in clinical imaging [2–5].
One of the major questions is whether or not PET/MRI is
capable of replacing PET/CT for certain clinical indications
and which are those indications.
Building an integrated PET/MRI scanner is a challenge
due to the different nature of MR and PET technology. The
static magnetic field required for MR interferes with the PET
detectors introducing signal distortions and the available
space is constrained because the MR bore is narrow.
These challenges are partly overcome by introducing
solid-state detectors that enable the placement of the PET
ring inside the MR bore, leading to an integrated geometry
which makes the scanner field of view (FOV) narrower as
well as longer. PET/MRI has shown partly enhanced PET-
performance due these new detectors and geometry provid-
ing higher sensitivity. However, previously reported whole-
body systems based on solid-state detectors did not offer
high enough sensitivity and time-of-flight performance and
thus still provided inferior image quality compared to
standard PET/CT [6]. Another study, although, assessed a
dedicated PET brain insert prototype featuring solid-state
APD readout and has shown an image quality superior to
whole-body PET/CT or PET/MRI in brain imaging [7].
Now a new integrated PET/MRI scanner enabling TOF-
PET acquisition [8] with silicon photomultipliers (SiPMs) is
available and a comparison of the scanner’s PET perfor-
mance can be made with the gold standard TOF-PET/CT.
The purpose of this study was to evaluate the clinical
image quality of standard PET/CT with TOF (time-of-flight)
compared to the newly introduced TOF-PET/MRI as a




A total of 10 adult patients (5 brain scans and 5 whole-body
scans, mean age 52 years, range 32–75 years; 4 women, 6
men) referred for either staging or restaging/follow-up of
various malignant tumors participated in this prospective
study. Inclusion criteria were clinically indicated whole-
body 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]FDG) PET/CT
and willingness to participate in the additional PET/MRI. It
is important to stress at this point that for all cases, the PET/
CT examination was performed first and the PET/MRI
followed next. That is because the PET/CT is the standard
clinical procedure while the PET/MRI was used only for
research purposes when this study was conducted. Exclusion
criteria were claustrophobia, MR-incompatible implanted
medical devices (e.g., cardiac pacemakers, insulin pumps,
neurostimulators, cochlear implants), possible metallic frag-
ments in the body, or a body habitus that did not fit into the
PET/MRI gantry. This study was approved by the Institu-
tional Ethics Committee, and written informed consent was
obtained from all patients prior to the procedure.
Acquisition Hardware
A sequential TOF-PET/CT (Discovery 690 PET/CT, GE
Healthcare, Waukesha, WI) and SIGNA simultaneous TOF-
PET/MRI (Signa PET/MRI, GE Healthcare, Waukesha, WI)
were used.
The PET/CT system has a cylindrical geometry, formed
by a full ring of 24 detector modules. The PET tomograph
consists of LYSO (Lu1.8Y0.2 SiO5(Ce)) crystals with
dimensions of 4.2×6.3×25 mm3. The PET detection unit is
a block of 54 (9×6) individual LYSO crystals coupled to a
single squared photomultiplier tube with 4 anodes. The TOF
timing resolution is around 500 ps. The detector ring has a
face-to-face diameter of 81 cm with a transaxial field of view
of 70 cm and an axial field of view of 15.7 cm [9].
The TOF-PET/MRI system is a hybrid whole-body
scanner (Signa PET/MR, GE Healthcare, Waukesha, WI,
USA) combining a 3-T wide-bore MR system with TOF-
PET detector rings.
The PET system also has a cylindrical geometry, formed
by a full ring of 28 detector modules. The detector ring has a
face-to-face diameter of 62 cm, with a transaxial field of
view of 60 cm and an axial field of view of 25 cm. The
detectors are mounted on a custom radiofrequency body
coil, centered inside the MR gradient set of a GE Discovery
750w 3 T MR Scanner. Each detector module is individually
shielded and includes control electronics, a liquid-cooling
circuit, and a Cartesian array of 45×16 LYSO scintillator
crystals, each crystal with dimensions of 3.95×5.3×25 mm3
[8], covering roughly 64.5×250.0 mm [10] paired with
silicon photomultipliers (SiPMs) using tapered light




Patients fasted for 6 h before being injected with [18F]FDG.
The administered dose was 3 MBq/kg if the body weight
was less than 85 kg or 3.5 MBq/kg otherwise, with a mean
administered activity of 234.6 and 224.4 MBq for brain and
whole-body scans, respectively. After an uptake time of
60 min (range 55–80 min), the clinically indicated PET/CT
scan was performed according to standard imaging protocols
of our hospital. Data was acquired in 3D mode with scan
duration of 10 min for the brain scan and 2 min per bed
position for the whole-body scan. The low-dose CT (used
both for attenuation correction and diagnostic purposes) and
regular-dose CT scans were acquired during shallow
breathing. Scan parameters were as follows: tube voltage
120–140 kV, tube current with automated dose modulation
60–440 mA/slice, collimation 64×0.625, pitch 0.984:1,
rotation time 0.5 s, coverage speed 78 mm/s, field of view
(FOV) 50 cm, and images with a transverse pixel size of
0.625, and a slice thickness of 3.75 mm reconstructed in
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axial, coronal, and sagittal planes [11]. Different PET
reconstruction settings were tested in this study and will be
discussed in the following sections.
PET/MRI Imaging
After the PET/CT examination, the patient was moved to the
adjacent PET/MRI room, with a mean interim time of
15 min for brain scans (respectively 30 min for the whole-
body scans). The brain scans lasted for 20 min while the
whole-body scans were acquired with 4 min per bed
position. The reason for this acquisition times was to expose
both systems to the same amount of emitted counts (see also
BData Processing^).
Patients were positioned in supine position with the arms
down. Before the acquisition of the PET data, a whole-body
MR localizer scan was performed in craniocaudal direction.
The standard patient radiofrequency (RF) coil setup always
included a 19-channel head and neck unit, 16-channel upper
and lower anterior arrays, and a 19-channel central matrix
array (GE Healthcare, Waukesha, WI, USA).
Next, the three-dimensional emission scan was planned
and started. The operator is prompted for setting anatomical
boundaries. The default number of bed positions was six,
from the vertex of the skull to the mid-thighs, but adjustable
to meet every patient’s body length. During PET scanning, a
multi-station whole-body, 3D, dual-echo, RF-spoiled gradi-
ent recalled echo (SPGR) sequence (LAVA-FLEX) was
acquired for the purpose of PET attenuation correction. With
the two echoes, in-phase and out-of-phase images were
acquired and water-only and fat-only images were calculated
automatically [12, 13]. The sequence parameters were
repetition time (TR) 4.056 ms, echo time (TE) out-of-phase
1.116 ms, (TE) in-phase 2.232 ms, flip angle (FA) 12°, field
of view (FOV) 500×375 mm (frequency×phase), acquisition
matrix 256×128, 1 slab with 64×5.2-mm thick axial slices,
voxel size 1.95×2.93 mm, and 1 average. For attenuation
correction, the system only uses the body coil. The total
acquisition time per bed position was 18 s. The MR-based
attenuation correction algorithm uses an anatomical atlas for
the patient’s head region and an air, lung, and continuous
fat/water segmentation for the other body regions [11].
Data Processing
Our goal was to expose both systems to the same amount of
emitted signal in order to assess clinically their sensitivity
performance in conditions as similar as possible. Adminis-
tering a second tracer injection to the patient was not
possible, so we opted to adjust the acquisition times to
account for tracer decay between the acquisitions. This had
to be done retrospectively due to the unpredictable nature of
the time delay between scans.
The acquisition times were manually adjusted by un-
listing the list mode data, creating sinograms that could then
be compared for each acquisition time. The decay integrals
for the whole examination duration were extracted and
adjusted so that the PET/MRI and PET/CT emission data
were equivalent. The two resulting sinograms are then
representative of a situation in which the patient has received
the same injected activity for each scan.
For the brain scans, the original scan duration times were
10 and 20 min for PET/CT and PET/MRI, respectively.
After correcting for the decay integrals so that they were
equivalent, we calculated that PET/MRI acquisition time
matched the PET/CT acquisition time with a reduced scan
time of an average of 13:51±00:40 min.
For the whole-body scans, the original acquisition
times were 16 and 24 min for PET/CT and PET/MRI
(2 min/bed for 8 beds, 4 min/bed for 6 beds),
respectively. As explained above, the PET/MRI list mode
data were shortened to be equivalent to the PET/CT. The
resulting PET/MRI list modes were on average 03:26
±00:25 min/bed.
Our next step was to reduce both PET/CT and PET/MRI
acquisition times in fixed time frames to simulate how the
systems respond to lower count rates and to compare image
quality step by step with reduced acquisition times.
For the brain scans, we unlisted the emission data for
8:00, 6:00, 5:00, 4:00, and 3:00 min for PET/CT and the
corresponding equivalent times for PET/MRI were 11:06
±0:35, 8:18±0:35, 6:54±0:30, 5:30±0:30, and 4:07±0:30. For
the whole-body scans, we unlisted the emission data for
2:00, 1:40, 1:20, 1:00 min/bed, and 00:40, 00:30 s/bed for
PET/CT and the corresponding equivalent times for PET/
MRI were 03:26, 02:50, 02:14, 01:38, 01:08, and 00:53
±00:25.
Reconstruction methods were carefully selected to be as
similar as possible for both scanners. Thus, equivalent rather
than identical settings were required because the scanners
have different geometries, so parameters like z-axis resolu-
tion and transaxial FOV vary and the reconstructed images
would not fit for reliable comparison. This is due to the
different detector geometry between the two systems. The
LYSO crystals on both systems share the same thickness but
the PET/MRI has a slight advantage having smaller crystals
in both transaxial and axial directions which leads to
improved image resolution (e.g., transaxial spatial resolution
for PET/CT is 4.7 mm full width at half maximum (FWHM)
[9] while for PET/MRI is 3.9 mm FWHM [8] at 1 cm from
FOV center). Both emission data were iteratively recon-
structed (VUE Point FX), TOF-OSEM (3 iterations, 16
subsets), reconstruction matrix 256×256, with point-spread-
function, corrected in a standardized way (random, scatter,
and attenuation), 30 and 60 cm transaxial FOV for the brain
and whole-body, respectively, Gaussian post-filter 2.0 mm.
In order for the comparison to be the most reliable, no z-axis
filter was applied since longitudinal resolution between the
scanners varied.
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Quantitative Evaluation
Two-dimensional regions of interest (2D-ROIs) with sizes of
634.5 and 134.6 mm2 were drawn in the liver (on coronal
plane) and in the white matter of the brain (on axial plane),
respectively, at the same position for each of the images for
all acquisition times, for both PET/CT and PET/MRI, and
for all patients. Here, it should be noted that the 2D-ROIs
both in the liver and in the brain were drawn in healthy and
not pathological tissue. Mean signal values from all 2D-
ROIs were extracted and compared.
Clinical Evaluation
The acquired brain and whole-body PET/CT and PET/MRI
images were sent to a dedicated review workstation
(Advantage Workstation 4.6, GE Healthcare, Milwaukee,
WI), which allows for the simultaneous review of the PET/
CT and PET/MRI images. The images were reviewed
clinically and compared by a dually-board-certified
radiologist/nuclear medicine physician and a radiologist
with substantial experience in PET/CT in consensus.
Differences in the images were noted and assessed using a
4-point scale for the scoring of image quality (4=excellent,
3=good, 2=acceptable, 1=insufficient), image sharpness
(4=perfectly sharp, 3=good, 2=acceptable, 1=blurry), and
noise (4=no noise, 3=slight, 2=considerable, 1=unaccept-
able) while a 3-point scale is used for the artifacts (3=no
artifact, 2=slight, 1=considerable).
Statistical Evaluation
To assess the correlation between PET/CT and PET/MRI for
the liver and the brain, trend lines were drawn for the cluster
of the brain and for the cluster of the liver and the
coefficients of determination were obtained (Fig. 1, see
Suppl. Table 1). Each cluster consists of five sub-clusters
corresponding to the number of the patients. An additional
condition forced the linear regression to cross the origin
because zero uptake corresponds to zero standardized uptake
value (SUV) in both scanners.
Results
Quantitative Evaluation
The results of the quantitative evaluation on regions of
interest defined on the liver and white matter are shown in
Fig. 1. The average SUV in each ROI is represented by a
point in the scatter plot, with PET/CT SUV represented in
the x-axis and PET/MRI SUV on the y-axis. Connected sub-
clusters of points represent, for each patient, corresponding
measurements on a series of reconstructions with decreasing
acquisition time (hence mimicking the behavior of dose
reduction). Thus, each sub-cluster consists of six points
representing the SUV value for each acquisition time. Notice
how the obtained average uptake values for individual
patients are consistent between reconstructions and display
similar variability in the PET/CT and PET/MRI axes. As
expected, there is clear organization in two separate,
compact clusters for liver and white matter measurements.
Uptake values in the brain are estimated to be higher in PET/
MRI compared to PET/CT, whereas uptake values measured
in the liver are estimated to be lower. Notice that tracer
decay has been corrected for in this comparison.
The coefficient of determination (R2) between PET/CT
and PET/MRI for the liver cluster has a value of 0.61703
and for the brain cluster a value of 0.95895, showing that
there is strong correlation between PET/CT and PET/MRI
brain SUVs while there is a good correlation for the liver
SUVs.
Clinical Evaluation
The reconstructed PET/CT and PET/MRI datasets were
qualitatively evaluated. A set of anatomical landmarks were
scored for each patient and acquisition time. Table 1 and
supplementary Tables 2 to 4 summarize these results,
averaged over all patients. Table 1 shows the overall image
quality scores (see sample brain and whole-body images in
Figs. 6 and 7, respectively), both for brain and whole-body
studies. PET/MRI and PET/CT scores are provided in pairs,
in decreasing acquisition time steps. The corresponding
tables for the image sharpness (Suppl. Table 2), artifacts
(Suppl. Table 3), and noise (Suppl. Table 4) are provided as
Supplementary Material. There was a statistically significant
difference for body imaging in image quality (pG0.001),
image sharpness (pG0.001), and noise (pG0.001) while there
was no significant difference for artifacts (p90.05), showing
a superiority of PET/MRI versus PET/CT. Remarkably it
can be noticed that the differences in body imaging can be
seen in all categories and at all time point, except in artifacts.
However, no significant difference was noticed in brain
imaging where both imaging methods showed comparable
results (p90.05) (Figs. 2, 3, 4, and 5).
Discussion
To our knowledge, this is one of the first evaluations on
image quality comparing standard TOF-PET/CT and simul-
taneous TOF-PET/MRI with different imaging times. We
have shown that the PET component of the PET/MRI
provides higher overall image quality as perceived by a
clinical reader compared to PET/CT. Furthermore, the
quantitative evaluation of brain and whole-body studies
showed that PET/MRI and PET/CT do not calculate
equivalent SUV-values. While this can be partly justified
by bio-redistribution of the tracer, (as seen in Fig. 3 of [19]),
there is still a big SUV value difference for the ROI placed
in the liver around 35 to 40 %, while there is approximately
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Fig. 1 PET/CT average compared to the PET/MRI one for the brain (white matter) 2D-ROI and whole body (liver) 2D-ROI for all
patients and all reconstruction times. The black dots indicate the value of the 2D-ROIs, and the red and blue lines indicate the
brain sub-clusters (one for each patient) and the whole-body sub-clusters (one for each patient), respectively.
Table 1. Image quality scores for all anatomical regions assessed for all equivalent acquisition times for both PET/CT and PET/MRI, averaged over all five































4 3.8 3.8 3.6 3.8 3.8 3.6 3.8 2.8 2.8 2.8 2.8
Posterior limb
of internal capsule
4 4 4 3.8 3.8 3.6 3.6 3.4 3 2.8 2.6 2.8
Cerebellar vermis 3.4 3.6 3.4 3.4 3.2 3.2 2.6 2.8 2.4 2.2 2.2 2
Dentate nucleus 4 4 3.8 3.6 3.2 3.2 2.8 2.8 2.6 2.6 2.2 2
Gray/white matter
Cerebellar 3.8 3.8 3.6 3.8 3.4 3.4 2.8 3 2.4 2.2 2.2 2.2
Frontal 4 4 4 4 3.8 3.6 3.2 3.4 2.6 2.6 2.2 2.4
Insular 4 4 4 4 3.8 3.8 3.4 3.2 2.8 2.8 2.4 2.6
Occipital 4 4 4 4 3.6 3.6 3.2 3 2.6 2.6 2 2.2
Parietal 4 4 4 4 3.8 3.6 3.2 3 2.6 2.6 2.4 2.6
Temporal 4 4 4 4 3.8 3.8 3.4 3.4 2.8 2.8 2.6 2.8
Nucleus ruber 3.8 4 3.6 3.8 3 3.2 2.8 2.8 2.4 2.6 1.8 1.8
Optic nerve 2.6 2.6 2.6 2.6 2.4 2.4 1.6 1.8 1.4 1.4 1 1.2
Putamen vs. globus
pallidus
4 4 3.8 3.6 3.4 3.4 2.6 2.6 2.4 2.6 2 2
Tectum 3.6 3.8 3.4 3.6 2.8 3 2.6 2.8 2.2 2.4 1.6 1.6
2 min /bed 1:40 min/bed 1:20 min/bed 1:00 min/bed 40 s/bed 30 s/bed
Whole body
Blood pool (RA) 3.6 4 3.6 4 3.2 3.6 2.8 3.4 1.8 3 1.6 2.4
Bone marrow 3.2 3.8 2.8 3.8 2.2 3.2 2 2.8 1.2 2.2 1 1.6
Heart (LV-muscle) 3.6 3.8 3.6 3.8 3.4 3.6 3 3.4 2.2 3 1.8 2.6
Liver (right lobe) 3.6 4 3 3.8 3 3.4 2.2 2.8 1.4 2.4 1.2 1.6
Lung 3.2 4 3.2 3.8 2.8 3.2 2.4 3 1.6 2.2 1.4 1.8
Muscle 3.2 4 2.8 3.6 2 3.2 1.8 2.8 1.6 2.6 1.2 1.6
Spleen 3.4 3.8 3 3.6 2.6 3.4 2.2 3 1.4 1.8 1.4 1.2
Subcutaneous fat 3.6 4 3 4 2.4 3.6 2 3 1.6 2.6 1.2 2
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a 15 % SUV value difference for the ROI placed in the white
matter (see Suppl. Table 1).
In this study, we assessed the PET performance of both
PET/CT and PET/MRI scanners for five brain and five
whole-body studies. The PET/MRI acquisition time was
retrospectively adjusted for each patient to account for tracer
decay since the start of the PET/CT acquisition. This
ensured that the reconstructed images used for the evaluation
offered a fair comparison where both systems had been
exposed to equivalent amounts of the emitted signal (Figs. 6
and 7).
Additionally, the acquired datasets were then used to
simulate multiple acquisitions of decreasing scan time. This
was used to evaluate the performance of the PET component
at gradually lower count statistics, providing an estimate of
the dose reduction capabilities of the new scanner.
Objective evaluation of the reconstructed image was
based on region of interest analysis. 2D-ROIs were drawn
in the white matter of the brain and in the liver and the
average uptake values measured. As expected, the results
show that there is not always a quantitative equivalence
between PET/CT and PET/MRI uptake values. This could,
Fig. 2 Brain and whole-body image quality scores averaged over all anatomical regions and all five patients for equivalent
acquisition times for both PET/CT and PET/MRI.
Fig. 3 Brain and whole-body image artifact scores averaged over all anatomical regions and all five patients for equivalent
acquisition times for both PET/CT and PET/MRI.
740 K.G. Zeimpekis et al.: Image quality of PET in PET/MRI vs. PET/CT
of course, severely limit the compatibility of these modalities
in follow-up studies. On the other hand, biological redistri-
bution of the tracer during the time between PET/CT and
PET/MRI acquisitions can partly explain the SUV differ-
ences found in liver measurement, as previously reported in
[14]. Furthermore, Fig. 1 shows a clearly consistent behavior
for liver and white matter groups. As a matter of fact, the
Signa PET/MRI system uses different attenuation estimation
methods for the head (atlas-based) and the body (4-class
segmentation). Higher estimation of brain SUVs may
therefore be attributed to insufficient anatomical accuracy
of the atlas or insufficient constraints in the elastic
registration (e.g., skull thickening). The lower estimation of
the liver SUVs can be due to the attenuation of anterior
upper and lower coils not being accounted for (only head/
neck and bed coils are corrected for attenuation due to fixed
position regardless of patient size), or to minor inaccuracies
in the attenuation coefficients assigned to the segmented
tissue classes. Further investigation is required that can
ultimately lead to a fine-tuning of MRAC.
Clinical evaluation shows equivalent performance for
brain studies. This is coherent with literature [9, 15]. Most of
Fig. 4 Brain and whole-body image sharpness scores averaged over all anatomical regions and all five patients for equivalent
acquisition times for both PET/CT and PET/MRI.
Fig. 5 Brain and whole-body image noise scores averaged over all anatomical regions and all five patients for equivalent
acquisition times for both PET/CT and PET/MRI.
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the FOV of PET/MRI is not used, so sensitivity cannot be
taken advantage of and lead to improved image quality. This
is due to the fact that the slice-wise increase of sensitivity at
the isocenter is not large enough to make a noticeable
difference in brain images. Another reason for this observa-
tion could be that the image quality in brain PET/CT images
is already very good and that improvements due to increased
counts are hard to distinguish.
The image quality, sharpness, artifacts, and noise for
PET/CT and PET/MRI for all acquisition times were
clinically assessed and scored.
Clinical evaluation indicated better performance for the
whole-body studies. In this case, the bigger FOV of the PET/
MRI is fully used so higher sensitivity provides significantly
improved image quality compared to the PET/CT.
As a consequence of the improved quality, there is
potential for dose or acquisition time reduction in whole-
body studies. Taking the general image quality diagram and
going with a scoring of acceptable quality, calculating the
acquisition time values based on the horizontal shift of the
two curves on the plot, PET/MRI can provide a 37 % (32/
51 s for PET/MRI and PET/CT, respectively) reduction in
dose or acquisition time, result that is coherent with previous
data [16]. There are studies that have suggested further dose
reduction in PET/MRI with prolonging the acquisition time
[17] since MRI usually takes more time anyway, but this
depends on the clinical indication and the type of
examination. In any case, this is promising and should be
put to the test in a future study. On the contrary, what we
have shown is that taking advantage of the higher geometric
efficiency (factor of ~2 for PET/MRI compared to PET/CT)
and higher detector sensitivity of PET/MRI [10] dose
reduction can be achieved in PET/MRI with keeping the
acquisition times fixed. For a standard patient, this reduction
in injected activity means that the patient’s effective dose
can be reduced by 1.75 mSv. Instead of the standard injected
activity of 250 MBq, the patient can be injected with
157 MBq that will deliver 3 mSv instead of 4.75 mSv
(0.019 mSv/MBq for standard patient size [18]). From a
radiation protection perspective, this is consistent with the
ALARA principle [19] for keeping the exposure of the
patient to radiation as low as possible while at the same time
obtaining sufficient image quality.
Conclusion
In this study, we compared the PET performance of PET/
MRI and PET/CT for various acquisition times. The
quantitative results show differences for both brain and
whole-body studies. These differences may be explained by
bio-redistribution [20]. However, a preliminary check
suggests that the measured differences are not fully
accounted for by the referenced models [20]. Hence, other
causes must be investigated (e.g., minor deviations of patient
Fig. 6 Upper row: PET/CT and PET/MRI original acquisition time brain images with the drawn 2D ROI (green circle) in white
matter from one subject. Lower images: PET/CT and PET/MRI with 5 min acquisition time brain images with the drawn 2D ROI
(green circle) in the white matter.
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attenuation from the 4-tissue-class model or reconstruction
convergence differences). The clinical assessment of the
brain studies indicate that there is no significant difference
between the two scans while for the whole-body studies the
Fig. 7 Upper images: PET/CT and PET/MRI original acquisition time whole body images with the drawn 2D ROI (green circle)
on the coronal plane in the liver. Lower images: PET/CT and PET/MRI with 1 min per bed frame acquisition time whole body
images with the drawn 2D ROI (green circle) on the coronal plane in the liver.
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image quality and the sharpness are constantly higher for
PET/MRI with at the same time lower levels of noise and
same levels of artifacts compared to PET/CT. This overall
higher image quality, due to higher geometric efficiency and
detector sensitivity, suggests that the acquisition time or
injected activity can be reduced by at least 37 % on the PET/
MRI scanner.
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